Michael Aminoff, MD, DSc, FRCP

Director of the Parkinson's Disease and Movement Disorders Clinic

Dr. Michael J. Aminoff is an internationally recognized neurologist and expert in diagnosing and treating Parkinson's disease. His work focuses on treating Parkinson's disease, particularly issues involving movement and cognition, such as memory disturbances, perception and judgment.

Aminoff was born and educated in England, graduating from University College London in 1962 and from University College Hospital Medical School in 1965. He subsequently trained in neurology and neurophysiology at The National Hospital (Queen Square) in London, and in 1974 moved to UCSF where he has been a professor of neurology since 1982. He was director of the Clinical Neurophysiology Laboratories at UCSF until 2004, when he became executive vice chair of the department. He also directs the Parkinson's Disease Clinic and Research Center, a National Parkinson Foundation Center of Excellence.

Aminoff is the author of over 225 published medical or scientific articles, as well as the author or editor of some 29 books. His published scientific contributions led to the award of a Doctorate in Science, an advanced doctorate in the Faculty of Science, by the University of London in 2000. He is one of two editors-in-chief of the four-volume Encyclopedia of the Neurological Sciences (2nd edition, Academic Press, 2014), and one of the series editors of the multi-volume Handbook of Clinical Neurology (Elsevier). He was editor-in-chief of the journal Muscle & Nerve from 1998 to 2007 and serves on numerous other editorial boards. He was a director of the American Board of Psychiatry and Neurology for eight years, and chair of the board in 2011.

Aminoff received the Lifetime Achievement Award from the American Association of Neuromuscular & Electrodiagnostic Medicine in 2006, and the A.B. Baker Award of the American Academy of Neurology, for lifetime achievements and contributions to medical education, in 2007.

He is married and has three children, one a pediatric rheumatologist, another a federal defense attorney and the third an assistant district attorney.

Clinics

Parkinson's Disease and Movement Disorders Clinic
400 Parnassus Ave., Eighth Floor
San Francisco, CA 94143
Phone: (415) 353-2273
Fax: (415) 353-2898

Hours: Monday to Friday
8 a.m. – 5 p.m.

Conditions & Treatments

Academic Title

Professor

More about Michael Aminoff

Education

University of London 1965

Residencies

University College Hospital Medical School, United Kingdom, Neurology 1972

Selected Research and Publications

  1. Gibbons CH, Simon DK, Huang M, Tilley B, Aminoff MJ, Bainbridge JL, Brodsky M, Freeman R, Goudreau J, Hamill RW, Luo ST, Singer C, Videnovic A, Bodis-Wollner I, Wong PS. Autonomic and electrocardiographic findings in Parkinson's disease. Auton Neurosci. 2017 Jul; 205:93-98.
  2. Hauser RA, Li R, Pérez A, Ren X, Weintraub D, Elm J, Goudreau JL, Morgan JC, Fang JY, Aminoff MJ, Christine CW, Dhall R, Umeh CC, Boyd JT, Stover N, Leehey M, Zweig RM, Nicholas AP, Bodis-Wollner I, Willis A, Kieburtz K, Tilley BC. Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson's Disease: An Analysis of NET-PD LS1. J Parkinsons Dis. 2017; 7(1):117-127.
  3. Aminoff MJ. Review of Merritt's Neurology, 13th ed. JAMA Neurol. 2016 Jun 01; 73(6):763.
  4. Goudreau JL, Pérez A, Aminoff MJ, Boyd JT, Burau KD, Christine CW, Leehey M, Morgan JC. Choice of dopaminergic therapy among early, mild Parkinson disease subjects in North America. J Neurol Sci. 2016 Jul 15; 366:74-81.
  5. Bega D, Luo S, Fernandez H, Chou K, Aminoff M, Parashos S, Walker H, Russell DS, Christine CW, Dhall R, Singer C, Bodis-Wollner I, Hamill R, Truong D, Mari Z, Glazmann S, Huang M, Houston E, Simuni T. Impact of Depression on Progression of Impairment and Disability in Early Parkinson's Disease. Mov Disord Clin Pract. 2015 Dec; 2(4):371-378.
  6. Lotti M, Aminoff MJ. Evaluating suspected work-related neurologic disorders (clinical diagnosis). Handb Clin Neurol. 2015; 131:9-21.
  7. Fang JY, Pérez A, Christine CW, Leehey M, Aminoff MJ, Boyd JT, Morgan JC, Dhall R, Nicholas AP, Bodis-Wollner I, Zweig RM, Goudreau JL. Parkinson's disease severity and use of dopaminergic medications. Parkinsonism Relat Disord. 2015 Mar; 21(3):297-9.
  8. Aminoff M, Boller F, Swaab DF. Letter to the editor: comment on Koehler and Stahnisch's (2014) "three twentieth-century multiauthored neurological handbooks". J Hist Neurosci. 2014; 23(4):420-1.
  9. Hess CP, Christine CW, Apple AC, Dillon WP, Aminoff MJ. Changes in the thalamus in atypical parkinsonism detected using shape analysis and diffusion tensor imaging. AJNR Am J Neuroradiol. 2014 May; 35(5):897-903.
  10. Dhand A, Aminoff MJ. The neurology of itch. Brain. 2014 Feb; 137(Pt 2):313-22.
  11. Fanara P, Wong PY, Husted KH, Liu S, Liu VM, Kohlstaedt LA, Riiff T, Protasio JC, Boban D, Killion S, Killian M, Epling L, Sinclair E, Peterson J, Price RW, Cabin DE, Nussbaum RL, Brühmann J, Brandt R, Christine CW, Aminoff MJ, Hellerstein MK. Cerebrospinal fluid-based kinetic biomarkers of axonal transport in monitoring neurodegeneration. J Clin Invest. 2012 Sep; 122(9):3159-69.
  12. Voss TS, Elm JJ, Wielinski CL, Aminoff MJ, Bandyopadhyay D, Chou KL, Sudarsky LR, Tilley BC. Fall frequency and risk assessment in early Parkinson's disease. Parkinsonism Relat Disord. 2012 Aug; 18(7):837-41.
  13. Mittermeyer G, Christine CW, Rosenbluth KH, Baker SL, Starr P, Larson P, Kaplan PL, Forsayeth J, Aminoff MJ, Bankiewicz KS. Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease. Hum Gene Ther. 2012 Apr; 23(4):377-81.
  14. Gottwald MD, Aminoff MJ. Therapies for dopaminergic-induced dyskinesias in Parkinson disease. Ann Neurol. 2011 Jun; 69(6):919-27.
  15. Chou KL, Zamudio J, Schmidt P, Price CC, Parashos SA, Bloem BR, Lyons KE, Christine CW, Pahwa R, Bodis-Wollner I, Oertel WH, Suchowersky O, Aminoff MJ, Malaty IA, Friedman JH, Okun MS. Hospitalization in Parkinson disease: a survey of National Parkinson Foundation Centers. Parkinsonism Relat Disord. 2011 Jul; 17(6):440-5.
  16. Aminoff MJ, Christine CW, Friedman JH, Chou KL, Lyons KE, Pahwa R, Bloem BR, Parashos SA, Price CC, Malaty IA, Iansek R, Bodis-Wollner I, Suchowersky O, Oertel WH, Zamudio J, Oberdorf J, Schmidt P, Okun MS. Management of the hospitalized patient with Parkinson's disease: current state of the field and need for guidelines. Parkinsonism Relat Disord. 2011 Mar; 17(3):139-45.
  17. Forsayeth J, Bankiewicz KS, Aminoff MJ. Gene therapy for Parkinson's disease: where are we now and where are we going? Expert Rev Neurother. 2010 Dec; 10(12):1839-45.
  18. Valles F, Fiandaca MS, Eberling JL, Starr PA, Larson PS, Christine CW, Forsayeth J, Richardson RM, Su X, Aminoff MJ, Bankiewicz KS. Qualitative imaging of adeno-associated virus serotype 2-human aromatic L-amino acid decarboxylase gene therapy in a phase I study for the treatment of Parkinson disease. Neurosurgery. 2010 Nov; 67(5):1377-85.
  19. Faulkner LR, Juul D, Pascuzzi RM, Aminoff MJ, Crumrine PK, Dekosky ST, Jozefowicz RF, Massey JM, Pirzada N, Tilton A. Trends in American Board of Psychiatry and Neurology specialties and neurologic subspecialties. Neurology. 2010 Sep 21; 75(12):1110-7.
  20. Tien I, Glaser SD, Aminoff MJ. Characterization of gait abnormalities in Parkinson's disease using a wireless inertial sensor system. Conf Proc IEEE Eng Med Biol Soc. 2010; 2010:3353-6.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.